Gabapentin is FDA-approved specifically for postherpetic neuralgia, the nerve pain that lingers after a shingles rash has healed. It is one of the first-line treatments for this condition and is widely prescribed. However, it is not effective during the acute phase of shingles, when the rash is still active.
What Gabapentin Treats (and Doesn’t)
The distinction matters: shingles itself is a viral infection caused by the reactivation of the chickenpox virus, producing a painful, blistering rash that typically lasts two to four weeks. Postherpetic neuralgia (PHN) is the aftermath. It’s nerve pain that persists for months or even years after the rash clears, and it affects roughly 10 to 18 percent of people who get shingles. Gabapentin targets this lingering pain, not the infection or the acute rash.
Some clinicians have prescribed gabapentin during the active rash phase, hoping it might reduce acute pain or prevent PHN from developing. A double-blind, randomized controlled trial tested exactly this, starting gabapentin within 72 hours of rash onset and titrating up to 1,800 mg per day. The results were clear: gabapentin provided no significant relief from acute shingles pain and did not prevent postherpetic neuralgia. At 12 weeks, 18.2% of patients in the gabapentin group still reported pain, compared to 9.5% in the placebo group, a difference that was not statistically significant. So if you’re in the middle of an active shingles outbreak, gabapentin is unlikely to help.
How It Works on Nerve Pain
After shingles damages nerve fibers, those nerves can become hyperexcitable, firing pain signals even without a stimulus. Gabapentin works by binding to a specific part of the calcium channels on nerve cells, called the alpha-2-delta subunit. This binding gradually reduces the number of calcium channels that reach the nerve cell surface, which in turn dials down the release of pain-signaling chemicals between nerves.
This mechanism takes time. Research published in the Proceedings of the National Academy of Sciences demonstrated that gabapentin inhibits calcium currents only when applied chronically, not acutely. That explains why the medication needs days to weeks of consistent use before you feel its full effect, and why it doesn’t work as a quick fix for sudden pain.
How Well It Works
Gabapentin doesn’t eliminate pain for everyone, but it provides meaningful relief for a significant portion of people with postherpetic neuralgia. In clinical trials, roughly 25 to 29 percent of patients taking gabapentin experienced at least a 50% reduction in their daily pain scores, compared to about 12 percent of those on placebo. That means for every four to five people treated, roughly one additional person gets substantial relief beyond what a placebo would provide.
For those who do respond, the difference can be significant: better sleep, improved mood, and a return to daily activities that pain had made difficult. For those who don’t get enough relief from gabapentin alone, it is sometimes combined with other treatments such as topical patches or low-dose antidepressants that also target nerve pain pathways.
What to Expect With Dosing
Gabapentin is typically started low and increased gradually. The usual starting point for postherpetic neuralgia is 300 mg taken as a single dose in the evening. From there, the dose is slowly raised over days to weeks based on how you respond and what side effects you experience. The upper limit is generally 1,800 mg per day, split into multiple doses.
This gradual approach, called titration, serves two purposes. First, it lets your body adjust to the medication and reduces the chance of side effects like dizziness and drowsiness, which are most common early on. Second, because gabapentin’s mechanism involves slowly reducing calcium channel activity at nerve surfaces, ramping up the dose gives the drug time to build its effect. Most people notice improvement within one to two weeks of reaching an effective dose, though it can take longer.
People with reduced kidney function need lower doses because gabapentin is cleared almost entirely by the kidneys. Dose adjustments are based on kidney filtration rate. Someone with moderately reduced kidney function might take 900 mg per day, while someone with severely impaired kidneys might take as little as 300 mg a few times per week. This is something your prescriber will calculate based on bloodwork.
Common Side Effects
The most frequent side effects are dizziness and drowsiness, which is why the first dose is usually taken in the evening. These tend to be worst during the first week or two and often improve as your body adjusts. Other commonly reported effects include mild swelling in the hands or feet, unsteadiness, and fatigue. For older adults, the dizziness and balance issues deserve particular attention because they can increase fall risk.
Gabapentin does not carry the same risk of liver damage or stomach bleeding associated with long-term use of common painkillers like ibuprofen or naproxen, which makes it a safer option for ongoing nerve pain management. It also has a lower addiction potential compared to opioid painkillers, though physical dependence can develop with prolonged use, meaning it should be tapered gradually rather than stopped abruptly.
How Gabapentin Compares to Pregabalin
Pregabalin works through the same mechanism as gabapentin, binding to the same calcium channel subunit, but the two aren’t identical in practice. A large systematic review and meta-analysis found that pregabalin produced modestly better pain relief on standardized pain scales over 12 to 14 weeks. Pregabalin also led to better quality-of-life scores and lower opioid use among patients. Total treatment costs between the two were not significantly different, though pregabalin is sometimes more expensive out of pocket depending on insurance coverage.
Despite this, gabapentin remains a common first choice because it has a long track record, is available as a low-cost generic, and many patients respond well to it. Pregabalin is often tried when gabapentin provides insufficient relief or causes bothersome side effects. Both are considered first-line options for postherpetic neuralgia in clinical practice guidelines, alongside certain antidepressants and topical treatments.